3
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Cytarabine
3
venetoclax
2
fludarabine
2
olverembatinib
1
ibrutinib
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
brexucabtagene autoleucel
1
axicabtagene ciloleucel
1
Surveys and Questionnaires
1
Ropivacaine
1
Platelet Transfusion
1
Melphalan
1
Maintenance
1
Magnetic Resonance Spectroscopy
1
Leukapheresis
1
Lenalidomide
1
JNJ-64619178
1
JNJ-64264681
1
Inosine Monophosphate
1
Imatinib Mesylate
1
Dexamethasone
1
Daunorubicin
1
Cyclophosphamide
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Enrolling by invitation
×
Inosine Monophosphate
×
Other hematologic neoplasm
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled